Welcome to our dedicated page for Nuvalent SEC filings (Ticker: NUVL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nuvalent, Inc. (NUVL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Nuvalent is a clinical-stage biopharmaceutical company listed on The Nasdaq Global Select Market, and its filings offer detailed information on clinical progress, financing activities, and key business agreements related to its targeted oncology pipeline.
Recent Form 8-K filings describe pivotal and preliminary data for neladalkib in ALK-positive NSCLC from the ALKOVE-1 Phase 1/2 trial, pivotal data for zidesamtinib in ROS1-positive NSCLC from the ARROS-1 Phase 1/2 trial, and the initiation of the ALKAZAR Phase 3 trial in TKI-naïve ALK-positive NSCLC. Other 8-Ks outline the completion and FDA acceptance of a New Drug Application for zidesamtinib in TKI pre-treated ROS1-positive NSCLC, plans for an NDA submission for neladalkib, and the assignment of a PDUFA target action date for zidesamtinib.
Filings also document Nuvalent’s capital markets activity, including an underwriting agreement for a public offering of Class A common stock under an automatically effective shelf registration statement on Form S-3, and the company’s estimate that proceeds from the offering, together with existing cash, cash equivalents, and marketable securities, would fund operations into 2029. Additional disclosures cover a preexisting royalty interest on future net sales of neladalkib and zidesamtinib, as well as periodic 8-Ks furnishing quarterly financial results press releases.
On Stock Titan, these SEC filings are paired with AI-powered summaries that highlight the main points of each document, helping readers quickly understand clinical data updates, NDA milestones, financing terms, and other material events. Users can review 10-K and 10-Q reports, 8-K current reports, registration statements, and exhibits, and use the AI-generated insights to navigate lengthy technical and legal language more efficiently while researching NUVL.
Form 4 Overview – Nuvalent, Inc. (NUVL)
On 06/26/2025, Chief Development Officer Darlene Noci reported a series of option exercises and related open-market sales under a pre-arranged Rule 10b5-1 trading plan dated 11/18/2024.
- Option exercise: 4,000 Class A common shares were acquired via option exercise at an exercise price of $27.85 per share.
- Dispositions: The exact 4,000 shares were immediately sold in three blocks: 85 sh at a weighted average $77.38, 3,609 sh at $78.70, and 306 sh at $79.15. Aggregate proceeds approximate $311 k, implying a spread of roughly $50 per share over the exercise price.
- Post-transaction holdings: Noci’s direct ownership declined from 52,034 to 48,034 shares (-7.7%). She retains 138,329 stock options expiring 01/06/2033.
No other equity classes or derivative instruments were reported. All transactions were effected under a 10b5-1 plan, suggesting routine portfolio management rather than discretionary selling.
Nuvalent, Inc. (NUVL) – Form 4 insider transaction summary
Chief Scientific Officer Henry E. Pelish reported a series of option exercises and related open-market sales executed on 06/25/2025 and 06/27/2025 under a Rule 10b5-1 trading plan adopted on 11/01/2024.
- Options exercised (Code “M”): 10,800 Class A shares in four tranches – 3,677 and 347 shares at a $27.85 strike (options granted 01/06/2023) and 4,953 and 1,823 shares at a $29.33 strike (options granted 03/01/2023).
- Shares sold (Code “S”): 10,800 Class A shares at weighted-average prices of $79.87 (range $79.80-$79.92) on 06/25/2025 and $79.92 (range $79.80-$80.00) on 06/27/2025.
- Ownership impact: Pelish’s direct Class A common-stock holding remains unchanged at 63,101 shares after the paired exercise-and-sell transactions, indicating a cashless exercise structure.
- Remaining derivative holdings: 28,328 options at a $27.85 strike (expiring 01/06/2033) and 25,299 options at a $29.33 strike (expiring 03/01/2033) are still outstanding.
No new shares were added to, or removed from, insider ownership; the activity primarily generated liquidity while maintaining the existing equity stake. Investors typically view such neutral, plan-based sales as having limited informational content, though they can add modest selling pressure near the $80 trading level.
Nuvalent officer Alexandra Balcom filed Form 144 indicating intent to sell 129,480 shares of Class A common stock with an aggregate market value of $10,358,400 through J.P. Morgan Securities. The planned sale represents approximately 0.2% of the company's 66.37 million outstanding shares.
The securities to be sold were acquired through two transactions:
- 122,396 shares via stock option exercise on June 27, 2025
- 7,084 shares from RSU vesting on January 6, 2025
The sale is being executed under a Rule 10b5-1 trading plan adopted on December 12, 2024. Some transactions will involve cashless option exercises within 3 months of filing. Notably, Balcom has not sold any company securities in the past 3 months. The filing includes standard attestation that the seller has no knowledge of material adverse non-public information.
Nuvalent Officer Darlene Noci has filed Form 144 indicating intent to sell 12,000 shares of Class A Common Stock through J.P. Morgan Securities, with an aggregate market value of $948,840. The sale is planned for June 26, 2025, on the NASDAQ exchange.
The securities were acquired through a stock option exercise on June 26, 2025. The filing reveals a consistent pattern of previous sales by Noci over the past three months:
- March 27, 2025: 4,000 shares ($292,482)
- April 29, 2025: 4,000 shares ($298,232)
- May 29, 2025: 4,000 shares ($285,238)
The sales are part of a Rule 10b5-1 trading plan adopted on November 18, 2024, and will be executed through cashless option exercises within three months of the filing date. Total shares outstanding: 66,373,511.